Cardiff Oncology (NASDAQ:CRDF) is an oncology specialist that had a fantastic year in 2020. The market is excited about the biotech's lead molecule, onvansertib, because it might work to defeat cancer caused by the KRAS mutation, a significant market opportunity.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,